Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Ch...(nd triggers NSCLC cell death throughapop...)

Date:12/20/2007

nd triggers NSCLC cell death through apoptosis; and (3) HGS- ETR1 inhibits NSCLC tumor growth in xenograft models of NSCLC, and can induce significant tumor regression in certain xenograft models of the disease. HGS preclinical studies also show that the activity of HGS-ETR1 in NSCLC models may be increased by co-treatment with chemotherapeutic agents including carboplatin and taxanes such as paclitaxel. The results of preclinical studies in a number of NSCLC cell lines showed that combining HGS-ETR1 with these chemotherapeutic agents resulted in increased cancer cell-killing ability despite resistance to mapatumumab alone, indicating a synergistic interaction. The combination of carboplatin, a taxane and HGS-ETR1 resulted in tumor regression and sustained reduction in tumor growth in a xenograft model of NSCLC that was significantly greater than any of the agents alone or the combination of carboplatin and a taxane.

The results of an earlier Phase 2 clinical trial of HGS-ETR1 to evaluate its safety as a single agent in patients with advanced non-small cell lung cancer showed that the drug was generally well tolerated and could be administered safely and repetitively, with no patients discontinuing therapy due to drug-related toxicity. Patients participating in the earlier study previously had received up to seven different cancer treatment regimens (median of three). Stable disease was observed in 29 percent (nine out of 32) of the patients treated, with eight patients receiving at least four cycles of therapy. The results, along with the results of other clinical and preclinical studies, support further evaluation of HGS-ETR1 in combination with chemotherapy agents.

About Non-Small Cell Lung Cancer

Non-small cell lung cancer accounts for approximately 75-80% of all lung cancers. It is estimated that more than 170,000 new cases and more than 160,000 deaths occur annually in the United States alone. It is currently the leading cause of cancer de
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources